{"id":24925,"date":"2024-08-23T14:53:16","date_gmt":"2024-08-23T12:53:16","guid":{"rendered":"https:\/\/mabdesign.fr\/?p=24925"},"modified":"2025-03-27T10:59:18","modified_gmt":"2025-03-27T09:59:18","slug":"the-immuno-oncology-market","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/the-immuno-oncology-market\/","title":{"rendered":"The immuno-oncology market"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

By mobilizing the patient’s immune system to fight cancer cells, immunotherapy offers new prospects for treating different types of tumor, some of which were previously considered incurable. The immuno-oncology market is experiencing exponential growth, fuelled by scientific and technological advances, massive investment in research and development, and a growing number of regulatory approvals for innovative treatments such as Immune<\/em> Checkpoint Inhibitors (ICIs),Chimeric Antigen Receptor-T cell (<\/em>CAR-T) therapies, and therapeutic cancer vaccines. <\/strong><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Classification of biotherapies in oncology<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Biotherapies can be divided into three main families: therapeutic proteins, vaccines and advanced therapy medicinal products (ATMPs). To address the market for biotherapies in oncology, we will focus on new, particularly innovative therapeutic approaches: therapeutic antibodies, therapeutic vaccines, in vivo<\/em> gene therapies, ex vivo<\/em> gene therapies and cell therapies.<\/strong> <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"biologics\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Figure 1: Classification of biological products in the immuno-oncology market analysis<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The analysis in this article covers the market for therapeutic antibodies, ATMPs (ex vivo and in vivo gene therapies and cell therapies) and therapeutic vaccines.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Biotherapies are currently a minority on the market compared to small chemical molecules <\/strong>: this is also true for products positioned in oncology, with only 7% of the anti-cancer therapeutic arsenal being biomedicines. There is, however, a wide diversity of therapeutic modalities <\/strong>: vaccines, antibodies, recombinant proteins, cell-based therapies, and so on. Of the products on the market, 502 are unique<\/strong> biologics, the vast majority being therapeutic proteins. <\/p>\n

Biomedicines, on the other hand, account for 34% of the rich pipeline, with 10,462 unique biomedicines<\/b> in development.<\/b> The majority are once again therapeutic proteins (49%), but ATMPs also account for a significant share of the overall distribution (36%), particularly in vivo <\/em> gene therapies (26%).<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Products on the oncology market<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t
<\/h5><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Products under development in oncology<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t
<\/h5><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Oncology products in development, by type<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t
<\/h5><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Figure 2: Distribution of biologics and small molecules marketed and under development in oncology.<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Left – Distribution of marketed oncology products.
\nCenter – Distribution of products under development in oncology.
\nRight – Focus on the distribution of biological products under development in oncology. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Market dynamics and trends<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The immuno-oncology market has been growing<\/strong> for over a decade.
\nIts expected compound annual growth rate (CAGR) is between 9 and 12%<\/strong> between 2023 and 2030*.
\nThis rapid expansion is fuelled by major deals: big pharma and biotech companies are looking to strengthen their immuno-oncology portfolios, which translates into buyouts and collaborations<\/strong> with start-ups, biotechs or cutting-edge research institutes.
\nThe significant increase in the number of clinical trials and new treatment approvals also reflects the market’s attractiveness and growth potential.
\nIn 2023, 9 new biomedicines were approved in immuno-oncology.<\/strong> <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"march\u00e9\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
new biomedicines approved in 2023 in immuno-oncology<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t
\n\t\t\n\t\t\t<\/div>\n\t\n
\n
\n <\/div>\n<\/div>\n